Dissertation > Excellent graduate degree dissertation topics show

Budesonide Impact on the Expression of Pulmonary Surfactant Protein-A (SP-A) in Hyperoxia-induced Lung Injury in Neonatal Rats

Author: HeRong
Tutor: XiaoZhiHui
School: Suzhou University
Course: Pediatrics
Keywords: Pulmonary surfactant protein-A hyperoxia-induced lung injury neonatal rat budesonide
CLC: R722.19
Type: Master's thesis
Year: 2013
Downloads: 39
Quote: 0
Read: Download Dissertation

Abstract


Objectives:1. To establish a model of hyperoxia-induced lung injury in neonatal rats;2. To observe the histopathological changes in neonatal rat lung of hyperoxia-inducedinjury as well as its affecting the expression of SP-A mRNA and protein by comparingwith control group, and to study the role of SP-A in the development of hyperoxia-inducedlung injury;3. To observe whether the inhaled corticosterroids, budesonide, has a protective effectto hyperoxia-induced injury and affects the expression of SP-A, and in order to provide atheoretical evident for clinical treatments of hyperoxia-induced lung injury.Method:The108neonatal SD rats (less than1day after birth, no male or female) wererandomly divided into3groups: Group Ⅰ,Air Group (Control Group); Group Ⅱ,Hyperoxygen and Saline Group (Hyperoxia Group); Group Ⅲ,Hyperoxygen andBudesonide Group (Interfering Group). Each group had36rats.Group Ⅰ was incubated in normal air. Group Ⅱ and Ⅲwere both exposed in specialoxygen boxes, and the oxygen concentration was continuously to90%-95%.In daily GroupⅡ was inhaled10ml of saline. And at the same time, Group Ⅲwas inhaled10ml ofdissolved BUD saline (with BUD2mg).The rats were executed on the3th,7thand14thday. Using bronchoalveolar lavaging tomeasure the protein level in lavaging fluid; Taking the lung tissue to weight, afterwise dry,and calculate the wet/dry proportion;Using HE to observe the histopathologicalchanges;Using Westen Blot to measure the level of SP-A protein in lungs;Using RT-PCRto detect the expression level of SP-A mRNA. Result:1. The general condition: Group Ⅰ (Air Group) was viable and fed well. Group Ⅱ(Hyperoxia Group) was dull, apathetic, less active, even dyspnea after hyperoygen abortion.The situation of Group Ⅲ (Interfering Group) was between the former two.2. Lung histopathology: In Group Ⅰ (Air Group), the size, shape and distrubution ofalveoli were normal. No inflamation can be found. In Group Ⅱ (Hyperoxia Group), after3days of hyperoxygen, the small blood vessels expanded congestion, alveolar cavityenlarged and appeared red blood and inflammatory cells, pulmonary septal area fractured.After7days of hyperoxygen, inflammation, pulmonary edema, pulmonary hemorrhagewere more obvious, the pulmonary septal area got wider and the structure of lung tissuewas arranged disorder. After14days of hyperoxygen, the changes were more obvious, thestructure of lung tissue was more disorder, the pulmonary septal area got severe wider,significant fibrosis could be seen, the numbers of alveoli reduced evidently, alveolar cavityenlarged obviously. In Group Ⅲ (Interfering Group), comparing with Group Ⅱ, thestructure and morphology in the lung tissue were milder.3. The wet/dry porpotion (W/D) of lung tissue: on the3thand7thday of this study, theW/D in Group Ⅱis higher than Group Ⅰ (P<0.01). And on the14thday, it is moresignificantly higher than Group Ⅰ (P<0.01). However, comparing with Group Ⅱ, the W/Don the3th,7thand14thday is obviously reduced in Group Ⅲ (P<0.01).4. The level of the protein in bronchoalveolar lavage fluid (BLAF): on the3th,7thand14thday, the BLAF protein level in Group Ⅱ is higher than Group Ⅰ, the differences arestatistically significant (P<0.01). However, on the3thday the protein in Group Ⅲisdecreased comparing with Group Ⅱ (P<0.05),and on the7thand14thday the protein levelis significantly lower (P<0.01).5. The variation of the expression level of SP-A protein in lung tissue: the WestenBlot shows that on the3thday, the expression level of SP-A protein in Group Ⅱ is higherthan GroupⅠ(P<0.01), and on the7thand14thday the expression level is significantlylower (P<0.01). On the3thday, the expression level of SP-A protein in Group Ⅲisbetween Group Ⅰa nd GroupⅡ(P<0.05), and on the7thand14thday the expression levelis significantly increased comparing with Group Ⅱ(P<0.05).6. The variation of the expression level of SP-A mRNA in lung tissue: the RT-PCRshows that on the3thday, the expression level of SP-A mRNA in Group Ⅱis higher than GroupⅠ (P<0.05), on the7thday the expression level is lower and on the14thday theexpression level is significantly lower (P<0.01). On the3thday, the expression level ofSP-A mRNA in Group Ⅲ is between Group Ⅰ and GroupⅡ(P<0.05), and on the7thand14thday the expression level is significantly increased comparing with Group Ⅱ(P<0.05).Conclusion:1. The hyperoxygen treatment will cause lung injury in rats, and the injury willincrease with the extension of oxygen time.The main histopathological changes of lungtissue are local hyperemia, hemorrhage, inflammatory exudate, structure disorder,development disturbance, decrease in the number of alveolar and interstitial pulmonaryfibrosis.2. In the hyperoxia-induced lung injury, the expression level of SP-A mRNA andprotein is increased firstly and then decreased. The level is parallel with the degree of lunginjury. These findings suggest that there is a certain protective mechanism of the body inthe process of hyperoxia-induced lung injury, and the decrease or dysfunction ofpulmonary surfactant protein is an important factor.3. The inhaled corticosterroids, budesonide may promote the expression of SP-AmRNA and protein by enhancing antioxidation and antiinflammation, alleviate the lunginjury, and play a protective effect to hyperoxia-induced lung injury.

Related Dissertations

  1. The Effect on the COPD Patients in the Acute Phase Before and After Therapy with Budesonide Aerosol Therapy About Serum of Level of ICAM-1 and E-selection,R563.9
  2. The Significance of Triggering Receptor Expressed on Myeloid Cells-1(TREM-1) in Neonatal Rats Septicemia with E.coli,R363
  3. Changes of Per1 and Cry1 Genes’ Expression in HIBD Neonatal Rat Pineal Gland,R722.1
  4. An Experimental Study on Relationship between Activin A and Development of Oligodendrocytes in Neonatal Rats,R722.1
  5. Budesonide / formoterol small airway function of children with moderate asthma,R725.6
  6. Polymorphisms of Surfactant Protein D and Association between Polymorphisms and Bronchopulmonary Dysplasia in Han Racial Wuhan Newborns,R722.1
  7. The Experimental Research of VEGF Transfected Neural Stem Cells for the Treatment of Cerebral Palsy in the Neonatal Rats,R742.3
  8. With chitosan / collagen composite scaffold for cardiac tissue engineering experimental study,R318.08
  9. Thymic stromal cells produce the hormone expression in A549 cells and its drug,R96
  10. Different doses of inhaled budesonide treatment of COPD exacerbations efficacy studies,R563.9
  11. Time to Leave the Needle in Different Neonatal Hypoxic Ischemic Encephalopathy Rat Brain Neural Stem Cells,R245
  12. Pharmacokinetic Study of New Formulations of Two Synthetic Glucocorticoids,R96
  13. Therapeutic Effects of High Frequency Jet Ventilation Combined with Tracheal Gas Insufflation on Acute Lung Injury,R563.8
  14. Mechanisms of JNK Signaling Pathway in Mouse Model of Allergic Rhinitis,R765.21
  15. Effect of Budesonide on the Expression of IL-12 in Animal Model of Minimal Persistent Inflammation of Allergic Rhinitis in Rats,R765.21
  16. Naloxone on neonatal rats with hyperoxia lung injury in rats,R722.1
  17. Reduning injection of neonatal rats hyperoxia-induced lung injury in rats,R285.5
  18. Effects of Using Dexamethasone in Different Time on Injury Lung in Neonatal Rats Which of Hyperoxia,R722.1
  19. The Influence and Mechanism of Budesonide Combined with Montelukast to Airway Remodeling of Asthma Mice,R562.25
  20. Nebulized Budesonide in Treament of Acute Exacerbations of Chronic Obstructive Pulmonary Disease,R563.9
  21. The Comparison of Effect of Symbicort Turbuhaler80ug/4.5ug Combined with Anhydrous Theophylline Sustained Tablets and Symbicort Turbuhaler160ug/4.5ug in the Treatment of Patients with Moderate Bronchial Asthma,R562.25

CLC: > Medicine, health > Pediatrics > Newborns, premature children disease > Neonatal disease > To neonatal Other disease
© 2012 www.DissertationTopic.Net  Mobile